Quarterly ResultAug 4, 2026, 04:15 PM
Spyre Therapeutics Reports Q2 2026 Results, Positive Clinical Data, $1.1B Cash
AI Summary
Spyre Therapeutics reported its second quarter 2026 financial results, including a net loss of $36.2 million, while maintaining a strong cash position of $1.1 billion, providing a runway into the second half of 2029. The company announced positive topline induction data for SPY001 and SPY002 from the SKYLINE trial, demonstrating best-in-class efficacy potential and a consistent safety profile. Enrollment for the SKYWAY basket trial was completed, and Spyre remains on track for six proof-of-concept Phase 2 readouts in 2026, including key data for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $1,145.3 million as of June 30, 2026.
- Expected cash runway extends into the second half of 2029.
- Net loss for the second quarter of 2026 was $36.2 million.
- Research and Development (R&D) expenses increased to $65.5 million in Q2 2026.
- General and Administrative (G&A) expenses were $16.1 million in Q2 2026.
- Recognized a $40.0 million gain from a milestone related to the sale of pegzilarginase.
- SPY001 and SPY002 showed statistically significant reductions of 9.2 and 10.7 points in Robart’s Histopathology Index.
- SPY001 and SPY002 achieved clinical remission rates of 40% and 33%, respectively.
- Remain on track for 6 proof-of-concept Phase 2 readouts in 2026.
Price Impact
More from SYRE